DaVita Inc. (NYSE:DVA) Holdings Raised by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S grew its stake in shares of DaVita Inc. (NYSE:DVA) by 153.0% during the 4th quarter, HoldingsChannel reports. The fund owned 131,873 shares of the company’s stock after acquiring an additional 79,742 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in DaVita were worth $19,722,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Invesco Ltd. grew its stake in DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock valued at $237,716,000 after purchasing an additional 275,284 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after buying an additional 92,014 shares in the last quarter. Amundi increased its holdings in DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after buying an additional 240,126 shares during the last quarter. Epoch Investment Partners Inc. acquired a new stake in DaVita in the fourth quarter valued at approximately $55,100,000. Finally, KBC Group NV grew its position in DaVita by 0.8% in the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock worth $47,281,000 after acquiring an additional 2,636 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Price Performance

Shares of NYSE:DVA opened at $140.21 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The business has a 50 day moving average price of $149.13 and a 200 day moving average price of $156.00. The company has a market cap of $11.22 billion, a price-to-earnings ratio of 13.05, a PEG ratio of 1.07 and a beta of 1.04. DaVita Inc. has a twelve month low of $128.69 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. StockNews.com raised DaVita from a “hold” rating to a “buy” rating in a research report on Thursday, April 10th. Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Barclays boosted their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.